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SUMMARY TRIAL/ORAL MEDICINE
Design Randomised controlled trial.
Intervention Patients with a validated history of at least three episodes of idiopathic recurrent aphthous stomatitis were randomised to either a once-daily multivitamin containing 100% of the U.S. reference daily intake (RDI) of essential vitamins or a placebo for at least one year.
Outcome measure Number of new RAS episodes, mouth pain, normalcy of diet and medication compliance.
Results There were no significant differences in mean number of new RAS episodes between the multivitamin (4.19 episodes) and placebo There was no correlation between frequency of recurrences and vitamin B 12 baseline levels.
Patients were requested to keep a record of medication intake and in the case of a RAS episode, its duration, pain and normalcy of diet.
Patients were evaluated at six and twelve months and they were requested to come during RAS episodes. Of the 575 episodes that underwent a clinical examination 13% were not RAS.
No differences between groups were observed in any of the studied outcomes over the duration of the study.
The investigators faced issues with patient compliance.
Compliance could play a role in the lack of observed effect.
Volkov and colleagues in 2009 1 reported 74% success in preventing episodes over a six-month period by using a much higher concentration of a sublingual vitamin B 12 tablet available over the counter.
Besides the dosage, we may need to consider that the delivery system could have an effect on the treatment success.
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Commentary
This randomised controlled trial investigated the effect of a daily multivitamin tablet on the number and severity of recurrent aphthous stomatitis (RAS) episodes in patients that experienced at least three RAS events in the previous year.
The study was designed with the intention of possibly identifying a low-cost, non-toxic product to prevent RAS that does not even require invasive baseline testing.
As the authors explained, the aetiology of RAS is not completely understood. As a result there are many therapeutic approaches with a larger number of topical options and less numerous systemic therapies. Most topical treatments are used to provide symptom relief while systemic therapies are being studied to prevent or limit the number and duration of recurrences, with less success.
